---
layout: default
title: Angiotensin Ii
parent: 僅模型預測 (L5)
nav_order: 51
evidence_level: L5
indication_count: 10
---

# Angiotensin Ii
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Angiotensin II: From Distributive Shock (Vasopressor) to Mitochondrial Oxidative Phosphorylation Disorder Due to Nuclear DNA Anomalies

## One-Sentence Summary

Angiotensin II is an endogenous vasoconstrictor octapeptide approved in major markets (FDA 2017, EMA 2019, as Giapreza®) as a vasopressor for refractory distributive/septic shock, but it has no marketing authorization in Taiwan.
The TxGNN model predicts it may be effective for **Mitochondrial Oxidative Phosphorylation Disorder Due to Nuclear DNA Anomalies** (rank 1, score 92.47%),
with **0 clinical trials** and **0 publications** currently supporting this specific direction.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not approved in Taiwan; globally approved as vasopressor for distributive/vasodilatory shock (Giapreza®) |
| Predicted New Indication | Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies |
| TxGNN Prediction Score | 92.47% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on publicly known information, Angiotensin II is an endogenous octapeptide that acts primarily through angiotensin II type 1 receptors (AT1R) and type 2 receptors (AT2R). Its major downstream effects include vasoconstriction, aldosterone secretion, sodium reabsorption, and — critically — intracellular reactive oxygen species (ROS) generation via NADPH oxidase activation. Its efficacy as a vasopressor for distributive shock has been demonstrated in the Phase 3 ATHOS-3 randomised controlled trial.

Theoretically, Angiotensin II's capacity to generate ROS could intersect with mitochondrial biology: excessive ROS can impair mitochondrial membrane potential and suppress electron transport chain complex activities. In nuclear DNA-encoded mitochondrial disorders — where oxidative phosphorylation machinery is already compromised at the genetic level — there is a speculative possibility that modulating ROS signalling could influence disease expression. However, this mechanistic bridge is entirely hypothetical and works in both directions; administering Ang II would more plausibly worsen mitochondrial oxidative stress rather than ameliorate it.

No published preclinical studies, animal models, or mechanism papers directly link exogenous Angiotensin II administration to any therapeutic effect in nuclear DNA mitochondrial disorders. The TxGNN prediction most likely reflects network proximity between RAAS-related nodes and mitochondrial dysfunction nodes in the knowledge graph, rather than a directionally validated therapeutic hypothesis. Prediction credibility is considered very low.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Taiwan Market Authorization

Angiotensin II (DrugBank: DB11842) holds no marketing authorization in Taiwan. No TFDA-approved licenses are on record.

> **Context**: Angiotensin II injection (Giapreza®, La Jolla Pharmaceutical) received FDA approval (December 2017) and EMA approval (October 2019) for adults with septic or other distributive shock. Its absence from the Taiwan market means domestic safety and prescribing data (TFDA package insert) are unavailable, representing a blocking data gap for full safety evaluation.

---

## Safety Considerations

Please refer to the SmPC (Giapreza® European Summary of Product Characteristics or FDA Prescribing Information) for safety information.

> **⚠️ Critical mechanistic alert across all top-10 TxGNN predictions**: Evidence collected for the adjacent predictions (diabetic retinopathy ranks 2 and 4; diabetic cataract rank 5; and multiple cataract subtypes ranks 6–10) consistently shows that Angiotensin II acts as a **pathogenic mediator** in these conditions — not a therapeutic agent. The entire body of clinical trial evidence in these disease areas evaluates **blocking** Ang II via ARBs, ACE inhibitors, or mineralocorticoid receptor antagonists. Administering exogenous Ang II would be expected to **promote** AT1R-mediated VEGF upregulation, retinal vascular permeability, oxidative stress, and lens protein oxidation. This represents a fundamental mechanistic contradiction for the majority of top-ranked predictions and must be explicitly resolved before any repurposing programme could proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There is no clinical trial or literature evidence supporting Angiotensin II for mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies, and the mechanistic basis is entirely speculative with no directional support. More broadly, a systematic concern applies across all top-10 TxGNN predictions: the existing evidence base for RAAS-related diseases consistently favours Ang II *antagonism*, not Ang II *administration* — raising the possibility that the model has captured disease association (Ang II is elevated in these conditions) rather than therapeutic direction.

**To proceed, the following is needed:**

- **MOA data** from DrugBank (Data Gap DG002): Confirm receptor binding profile, downstream signalling, and any known effects on mitochondrial function
- **TFDA package insert** (Data Gap DG001): Obtain key warnings, contraindications, and dosing parameters for full safety assessment
- **Mechanistic clarification**: Determine whether TxGNN's predictions represent true drug–disease therapeutic links or artefacts of RAAS disease-node clustering in the knowledge graph; a directionality audit of predicted indications is strongly recommended
- **Preclinical evidence screen**: Search for any in vitro or animal model data showing benefit of Ang II (not RAAS blockers) in mitochondrial disorders or nuclear DNA defect models
- **Alternative indication review**: Re-examine lower-ranked predictions outside the RAAS-associated disease cluster to identify any indications where Ang II administration (rather than blockade) could plausibly be beneficial, such as its established vasopressor role or potential applications in haemodynamic rescue scenarios
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

